RFK Jr on Joe Rogan: 14 Peptides Moving Out of Category 2 — FDA Panel Confirmed July 2026

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on The Joe Rogan Experience (Episode #2461) and made what may prove to be the most consequential statement about peptide regulation in years. Roughly 90 minutes into the conversation, Kennedy told Rogan that approximately 14 of the 19 peptides currently on the FDA’s Category 2 restricted list would be moved back to Category 1 — restoring their eligibility for compounding by licensed pharmacies.

The announcement sent ripples through the peptide community, the compounding pharmacy industry, and even public equity markets (HIMS stock surged approximately 13.5% on the day of the episode’s release). But what exactly did RFK Jr. say, what does it mean in regulatory terms, and — critically — what has actually happened since?

This article breaks down the full context: the FDA’s category system, the 19 peptides originally restricted, which 14 are expected to move, which may remain restricted, and what the confirmed July 2026 advisory panel means for the timeline.

April 2026 Update — FDA Advisory Committee Confirmed for July

Here’s what’s changed since the original Rogan episode:

The FDA has confirmed a two-day advisory committee meeting for late July 2026 focused on pharmacy compounding of peptides. Seven peptides are on the agenda for this first panel — including BPC-157, widely used for tendon and joint recovery, and TB-500, one of the most popular peptides in the tissue repair space.

The panel will consider whether these seven peptides should be added to the list of substances that can be routinely compounded by licensed pharmacies. A second advisory panel is scheduled by February 2027 for five additional peptides.

This is significant because it moves the reclassification from “RFK Jr. said something on a podcast” to “there’s a formal FDA process with confirmed dates.” The advisory committee is the mechanism through which the FDA evaluates the safety and suitability of bulk drug substances for compounding. Their recommendation carries substantial weight — and multiple outlets are reporting that the panel is expected to support the reclassification push.

What hasn’t changed: The formal updated Category list has not been published yet. The regulatory framework from before the Rogan episode technically remains in effect. But the distance between “policy signal” and “formal action” has narrowed considerably with these confirmed panel dates.

Key Sources on the July Panel

• STAT News: “FDA peptide advisers expected to support RFK Jr.’s legalization push” (April 15, 2026)
• NBC News: “RFK Jr. promotes peptides. Now the FDA weighs easing limits”
• PBS: “FDA to weigh easing limits on peptides favored by RFK Jr. and MAHA supporters”
• NPR: “The wellness world is eager for RFK Jr.’s promised move on peptides” (March 31, 2026)
• BioPharma Dive: “FDA moves toward easing restrictions on certain peptides”

Understanding the FDA Category System for Compounding

Before diving into what RFK Jr. announced, it helps to understand the regulatory framework at play. Under Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act, the FDA maintains a “bulks list” — a list of bulk drug substances that may or may not be used by compounding pharmacies to prepare patient-specific medications.

The FDA sorts these substances into three categories:

• Category 1 — Eligible for compounding. Licensed pharmacies can compound these substances into preparations with a valid prescription. This is the “green light” status.
• Category 2 — Significant safety concerns identified. Substances in this category cannot be compounded under 503A. Access through compounding pharmacies is shut off.
• Category 3 — Under evaluation. The FDA hasn’t made a final determination yet.

The distinction between Category 1 and Category 2 has enormous practical consequences. When a peptide sits in Category 1, a physician can write a prescription and a compounding pharmacy can prepare it. When that same peptide is moved to Category 2, that pathway is shut off entirely — the substance can only be obtained through an FDA-approved drug product (if one exists) or, in practice, not at all through legitimate channels.

This is why the reclassification matters so much. It’s not about making peptides “legal” — it’s about restoring a specific access pathway that millions of people and thousands of clinicians relied on. For a deeper look at the legislative side, see our article on the SAFE Act and peptide research in 2026.

How 19 Peptides Ended Up in Category 2

In September 2023, under the Biden administration, the FDA placed 19 peptides on the Category 2 list. The agency cited “significant safety risks” that made them unsuitable for compounding under Section 503A.

The move was controversial from the start. Critics — including many clinicians and researchers — argued that the Category 2 designation was overly broad, that the safety concerns weren’t well-supported by the available scientific literature for many of the listed peptides, and that the practical effect was to eliminate patient access to compounds that clinicians had been prescribing for years.

If you followed the Peptide Sciences shutdown, you already know how the ripple effects played out across the supplier landscape.

The full list of 19 peptides placed in Category 2 in September 2023:

1. AOD-9604
2. BPC-157
3. Cathelicidin LL-37
4. CJC-1295
5. Dihexa Acetate
6. Emideltide (DSIP)
7. Epitalon
8. GHK-Cu
9. Ibutamoren (MK-677)
10. Ipamorelin
11. Kisspeptin-10
12. KPV
13. Melanotan II
14. PEG-MGF
15. MOTS-C
16. Selank
17. Semax
18. Thymosin Alpha-1
19. TB-500 (Thymosin Beta-4 fragment)

September 2024: The First Round of Removals

In September 2024, the FDA removed five peptides from Category 2 based on nomination withdrawals:

• AOD-9604
• CJC-1295
• Ipamorelin
• Thymosin Alpha-1
• Selank

These removals were procedural — the nominations that placed them in Category 2 were withdrawn, and the FDA removed them accordingly. While this didn’t automatically restore them to Category 1 in all cases, it removed the explicit restriction.

Then, on January 7, 2025, the FDA published an updated interim policy on bulk drug substances used in compounding, further clarifying the regulatory landscape. The situation remained in flux heading into 2026.

What RFK Jr. Said on Joe Rogan (Episode #2461)

This brings us to February 27, 2026. During his appearance on The Joe Rogan Experience, HHS Secretary Kennedy directly addressed the peptide issue:

“My hope is that they’re going to get moved to a place where people have access from ethical suppliers.”

“We created the black market.”

Kennedy argued that the Category 2 restrictions had been counterproductive. Rather than protecting public safety, the restrictions had pushed users away from regulated compounding pharmacies and toward unregulated grey-market suppliers — the opposite of the intended effect. He stated that the FDA was “looking at the science” and indicated that approximately 14 of the remaining peptides could be reclassified.

The specific number — 14 out of the original 19 — is notable. When combined with the five already removed in September 2024, this accounts for all 19 originally listed peptides, with approximately five expected to remain under some form of restriction.

The 14 Peptides Expected to Move to Category 1

Based on RFK Jr.’s statements and subsequent reporting, the following 14 peptides are expected to be reclassified from Category 2 to Category 1:

• BPC-157 — one of the most popular peptides in the recovery space, widely used for tendon repair, joint healing, and gut health
• Thymosin Alpha-1 — used by practitioners for immune support and modulation
• TB-500 — tissue repair, flexibility, and recovery; a staple for athletes and people dealing with injuries
• AOD-9604 — studied for fat metabolism and body composition
• CJC-1295 — growth hormone releasing hormone analogue; often paired with Ipamorelin
• Ipamorelin — one of the cleanest growth hormone releasing peptides; popular for its selectivity
• Selank — anxiolytic peptide used for stress, anxiety, and mood regulation
• Semax — has built a following among people looking for sharper focus and cognitive performance without stimulants
• KPV — anti-inflammatory peptide studied for gut inflammation and skin health
• MOTS-C — mitochondrial peptide studied for metabolic function and exercise performance
• GHK-Cu — wound healing, skin remodeling, and anti-aging research
• Epitalon — telomerase and aging research
• Emideltide (DSIP) — sleep and stress response research
• Kisspeptin-10 — reproductive endocrinology research

Note that this list includes the five peptides already removed from Category 2 in September 2024 (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank). Their inclusion in the “14” likely reflects their formal reclassification into Category 1 status, rather than simply being removed from Category 2 without a definitive new designation.

The ~5 Peptides Expected to Remain Restricted

Approximately five peptides from the original 19 are expected to remain in Category 2 or under continued restriction:

• Melanotan II — has faced safety concerns from multiple international regulatory bodies
• Dihexa Acetate — limited human safety data relative to its potency
• PEG-MGF — synthetic growth factor fragment
• Cathelicidin LL-37 — antimicrobial peptide with complex safety profile
• Ibutamoren (MK-677) — technically a growth hormone secretagogue rather than a peptide; has been the subject of adverse event reports

Full Comparison Table: All 19 Peptides

Peptide	What It’s Known For	Sept 2024 Status	Expected New Status	July 2026 Panel?
AOD-9604	Fat metabolism, body composition	Removed from Cat. 2	Category 1	TBC
BPC-157	Recovery, tendon/joint healing, gut health	No change	Category 1	✓ On agenda
Cathelicidin LL-37	Antimicrobial peptide research	No change	Remains restricted	—
CJC-1295	Growth hormone support	Removed from Cat. 2	Category 1	TBC
Dihexa Acetate	Cognitive and neurotrophic research	No change	Remains restricted	—
Emideltide (DSIP)	Sleep and stress response	No change	Category 1	TBC
Epitalon	Telomerase activation, aging research	No change	Category 1	TBC
GHK-Cu	Wound healing, skin remodeling, anti-aging	No change	Category 1	TBC
Ibutamoren (MK-677)	GH secretagogue (not technically a peptide)	No change	Remains restricted	—
Ipamorelin	Growth hormone release, recovery	Removed from Cat. 2	Category 1	TBC
Kisspeptin-10	Reproductive health, fertility	No change	Category 1	TBC
KPV	Inflammation, gut health, skin health	No change	Category 1	TBC
Melanotan II	Melanocortin receptor, tanning research	No change	Remains restricted	—
PEG-MGF	Muscle tissue and recovery research	No change	Remains restricted	—
MOTS-C	Metabolic function, exercise performance	No change	Category 1	TBC
Selank	Stress, anxiety, mood regulation	Removed from Cat. 2	Category 1	TBC
Semax	Cognitive performance, focus, neuroprotection	No change	Category 1	TBC
Thymosin Alpha-1	Immune support and modulation	Removed from Cat. 2	Category 1	TBC
TB-500	Tissue repair, recovery, flexibility	No change	Category 1	✓ On agenda

Updated Regulatory Timeline

Date	Event	What It Means
September 2023	FDA places 19 peptides on Category 2	All 19 peptides barred from 503A compounding
September 2024	FDA removes 5 peptides from Category 2	AOD-9604, CJC-1295, Ipamorelin, TA-1, Selank removed following nomination withdrawals
January 7, 2025	FDA publishes updated interim policy	Clarifies compounding framework for bulk drug substances
February 27, 2026	RFK Jr. announces on JRE #2461	States ~14 peptides will move to Category 1
Late July 2026	FDA advisory committee meeting (confirmed)	Two-day panel evaluating first 7 peptides including BPC-157 and TB-500
By February 2027	Second FDA advisory panel	Five additional peptides to be evaluated
TBD	Formal updated Category list publication	Official reclassification — the date that actually changes the legal framework

Where Things Stand Now: What’s Changed and What Hasn’t

It’s been nearly two months since RFK Jr.’s Rogan appearance. Here’s the honest picture:

What’s changed:

• The FDA advisory committee meeting is confirmed with specific dates (late July 2026)
• Seven peptides are on the formal agenda — this isn’t speculation anymore
• Multiple major news outlets (STAT, NBC, PBS, NPR, BioPharma Dive) are reporting the panel is expected to support reclassification
• A second panel is scheduled for February 2027
• The regulatory machinery is moving in a specific, trackable direction

What hasn’t changed:

• No formal FDA regulatory action has been published yet
• The Category 2 designations technically remain in effect
• Compounding pharmacies still can’t compound Category 2 substances based on a podcast statement or news reports
• The formal reclassification requires the advisory committee’s recommendation AND FDA follow-through

The gap between “confirmed panel dates” and “published regulatory action” is still real — but it’s narrowing. For people who’ve been following the peptide space, the trajectory is clear. The question is no longer if but when and in what order.

The “Black Market” Argument

One of the more striking elements of RFK Jr.’s comments was his direct acknowledgment that the Category 2 restrictions had, in his view, created an unregulated market. His statement — “We created the black market” — echoed an argument that industry observers and clinicians had been making since the original 2023 restrictions.

The logic is straightforward: when people lose access to compounded peptides through regulated pharmacies, demand doesn’t disappear. It shifts to unregulated suppliers — often operating online, often outside the United States, and often without the quality controls that compounding pharmacies maintain. The result is that people end up using substances of unknown purity and potency, which is a worse safety outcome than the regulated compounding the restrictions were designed to address.

Whether you agree with this framing or not, it represents a significant rhetorical shift from the sitting HHS Secretary. The Biden-era FDA’s position was that Category 2 restrictions were necessary to protect patients. The current administration is signaling that the restrictions themselves may have introduced greater risk than the substances they were meant to control.

Market Reaction

The financial markets responded swiftly to RFK Jr.’s comments. Shares of Hims & Hers Health (NYSE: HIMS) surged approximately 13.5% on the day of the announcement. The market reaction underscores the commercial significance of peptide compounding access — the ability for 503A pharmacies to compound these substances represents a meaningful revenue stream for companies in the telehealth and compounding space.

What This Means If You Care About Peptides

If you’ve been using peptides for recovery, cognitive performance, immune support, or metabolic health — or if you’ve been watching from the sidelines waiting for clarity — here’s what matters:

1. Access is opening up, but it’s not a free-for-all. Category 1 status means compounding pharmacy access with a prescription. Not over-the-counter. Not unregulated online sales. A doctor writes a prescription, a licensed pharmacy compounds it.
2. Quality becomes the differentiator. When access through legitimate channels opens up, the companies that have been doing real testing — third-party COAs, batch-level purity verification — will stand out. The ones cutting corners will have nowhere to hide.
3. The timeline has specific dates now. July 2026 for the first seven peptides. February 2027 for five more. You can plan around that.
4. Research doesn’t stop. Whether a peptide is Category 1 or Category 2, the underlying research is the same. BPC-157’s mechanism of action doesn’t change because of a regulatory designation. What changes is how easily people can access it through regulated channels.

For those interested in the research behind specific peptides mentioned in this article, NorthPeptide maintains comprehensive research guides for BPC-157, TB-500, Semax, Selank, MOTS-C, and GHK-Cu, among others.

Looking Ahead

The next major milestone is the late July 2026 advisory committee meeting. That two-day panel will set the tone for everything that follows. If the committee recommends reclassification for the first seven peptides — and reporting suggests they will — expect the FDA to move relatively quickly on the formal Category list update.

The February 2027 panel for the remaining five peptides will complete the process RFK Jr. outlined on Rogan. Between those two dates, the peptide landscape in the United States will look fundamentally different than it has for the past three years.

We’ll continue updating this article as the regulatory situation develops. For a complete breakdown of all 14 peptides and what each one is used for, see our companion article: Which Peptides Are Being Reclassified in 2026? The Complete List.

---

Related Articles

• The SAFE Act and Peptide Research: What You Need to Know in 2026
• Peptide Sciences Shutdown 2026: What Happened and Where to Find Research Peptides
• What Peptide Reclassification Means for the Future of the Industry

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Obesity Medicine Association	2024	Position Statement FAQ	Compounded peptides — regulatory framework and clinical considerations	PMC11369382
Mancinelli et al.	2024	Review	FDA-approved peptide analogues — GLP-1, GIP, GHRH, and related frontiers	PMC10968328
Wang et al.	2023	Review	Prevalence of peptide therapeutic products — a critical review	PMC10655677
Nussinov et al.	2025	Review	Regulatory guidelines for analysis of therapeutic peptides and proteins	PMC11806371
Al Musaimi et al.	2025	Review	2024 FDA TIDES harvest — peptide and oligonucleotide approvals	PMC11945313
Gorman	2016	Commentary	FDA draft guidances on compounding — rules limiting distribution	PMC4959613
Driscoll	2018	Commentary	Compounding law five years later — FDA implementation and industry criticism	PMC5912243

Written by NorthPeptide Research Team